Our goal was to develop multimodality PET/OFI rotaxane conjugates that target prostate cancer by attaching a fluorescent probe and a 68Ga-radiolabelled metal-ion binding chelate to the biologically active PSMA targeting vector Lys-urea-Glu (Fig. 1). This evidence concerns the gene FOLH1 and prostate carcinoma.